Whitney & Co’s Sage Therapeutics SAGE Stock Holding History

Whitney & Co’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-14	Closed	-$2K	–	380
2018 Q3	$2K	Buy	+14	New	+$2.16K	﹤0.01%	471

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Whitney & Co's SAGE Position: Q4 2018 in Review

Whitney & Co sold out of Sage Therapeutics (SAGE) in Q4 2018, closing a stake of 14 shares — an estimated $2K sold.

Whitney & Co first reported a position in SAGE in Q3 2018 and held it in 1 quarter. The position peaked at $2K in Q3 2018. 248 funds tracked by Wall St. Rank hold SAGE as of Q4 2018.

Whitney & Co reported no remaining Sage Therapeutics position as of Q4 2018 after selling out during the quarter.
Whitney & Co sold 14 Sage Therapeutics shares in Q4 2018, an estimated $2K.
Whitney & Co first reported a position in Sage Therapeutics in Q3 2018 and held it in 1 quarter.
Whitney & Co's Sage Therapeutics position peaked at $2K in Q3 2018.
248 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2018.

Based on Whitney & Co's 13F filing for Q4 2018, filed 7 Feb 2019.